3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Sell
44
ACAD Quote, Financials, Valuation and Earnings
Last price:
$17.45
Seasonality move
:
15.41%
Day range:
$17.44 - $18.66
52-week range:
$14.15 - $31.10
Dividend yield:
0%
P/E ratio:
22.38x
P/S ratio:
3.12x
P/B ratio:
5.03x
Volume:
3.2M
Avg. volume:
3.1M
1-year change:
-42.43%
Market cap:
$2.9B
Revenue:
$726.4M
EPS (TTM):
$0.78
Analysts' Opinion
-
Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 6 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $24.95, ACADIA Pharmaceuticals has an estimated upside of 42.88% from its current price of $17.46.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 37% downside risk from its current price of $17.46.
Fair Value
-
According to the consensus of 12 analysts, ACADIA Pharmaceuticals has 42.88% upside to fair value with a price target of $24.95 per share.
ACAD vs. S&P 500
-
Over the past 5 trading days, ACADIA Pharmaceuticals has overperformed the S&P 500 by 1.39% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ACADIA Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ACADIA Pharmaceuticals has grown year-over-year revenues for 8 quarters straight. In the most recent quarter ACADIA Pharmaceuticals reported revenues of $250.4M.
Earnings Growth
-
ACADIA Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ACADIA Pharmaceuticals reported earnings per share of $0.20.
Enterprise value:
2.3B
EV / Invested capital:
--
Price / LTM sales:
3.12x
EV / EBIT:
20.85x
EV / Revenue:
2.52x
PEG ratio (5yr expected):
--
EV / Free cash flow:
11.55x
Price / Operating cash flow:
14.30x
Enterprise value / EBITDA:
18.79x
Gross Profit (TTM):
$851.3M
Return On Assets:
15.57%
Net Income Margin (TTM):
13.83%
Return On Equity:
27.32%
Return On Invested Capital:
27.32%
Operating Margin:
12.64%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $511.5M | $631.9M | $929.2M | $211.7M | $250.4M | |
| Gross Profit | $501.2M | $605.7M | $851.3M | $197.1M | $231.5M | |
| Operating Income | -$222.2M | -$154.4M | $112.2M | -$57.8M | $31.6M | |
| EBITDA | -$220.1M | -$150M | $124.5M | -$56.1M | $34.2M | |
| Diluted EPS | -$1.35 | -$0.92 | $0.78 | -$0.40 | $0.20 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $730.2M | $640.9M | $521.6M | $499.2M | $788.3M | |
| Total Assets | $795.7M | $717.7M | $602.5M | $632.5M | $976.9M | |
| Current Liabilities | $91.9M | $88.2M | $116.6M | $209.6M | $343.9M | |
| Total Liabilities | $140.8M | $150.7M | $176.8M | $270.4M | $399.7M | |
| Total Equity | $654.9M | $567M | $425.7M | $362.2M | $577.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$113.3M | -$92.5M | $202.7M | -$59M | $63.2M | |
| Cash From Investing | $162.5M | $14.6M | -$153M | $34.1M | -$82.5M | |
| Cash From Financing | $11M | $21.3M | $10.3M | $12.8M | $268K | |
| Free Cash Flow | -$113.3M | -$132.6M | $202.7M | -$59M | $63.2M | |
ACAD
Sector
Market Cap
$2.9B
$49.2M
Price % of 52-Week High
56.14%
48.57%
Dividend Yield
0%
0%
Shareholder Yield
-0.4%
-0.74%
1-Year Price Total Return
-42.43%
-30.94%
Beta (5-Year)
0.374
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$17.62
200-day SMA
Buy
Level
$16.42
Bollinger Bands (100)
Buy
Level
15.05 - 17.23
Chaikin Money Flow
Buy
Level
8.4M
20-day SMA
Sell
Level
$17.53
Relative Strength Index (RSI14)
Buy
Level
51.69
ADX Line
Buy
Level
32.58
Williams %R
Neutral
Level
-61.859
50-day SMA
Buy
Level
$16.70
MACD (12, 26)
Buy
Level
0.31
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
257.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.4338)
Buy
CA Score
(Annual)
Level (0.0295)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.4647)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Stock Forecast FAQ
In the current month, ACAD has received 6 Buy ratings 6 Hold ratings, and 0 Sell ratings. The ACAD average analyst price target in the past 3 months is $24.95.
-
Where Will ACADIA Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that ACADIA Pharmaceuticals share price will rise to $24.95 per share over the next 12 months.
-
What Do Analysts Say About ACADIA Pharmaceuticals?
Analysts are divided on their view about ACADIA Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ACADIA Pharmaceuticals is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is ACADIA Pharmaceuticals's Price Target?
The price target for ACADIA Pharmaceuticals over the next 1-year time period is forecast to be $24.95 according to 12 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is ACAD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ACADIA Pharmaceuticals is a Leans Bullish. 6 of 12 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of ACAD?
You can purchase shares of ACADIA Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ACADIA Pharmaceuticals shares.
-
What Is The ACADIA Pharmaceuticals Share Price Today?
ACADIA Pharmaceuticals was last trading at $17.45 per share. This represents the most recent stock quote for ACADIA Pharmaceuticals. Yesterday, ACADIA Pharmaceuticals closed at $17.46 per share.
-
How To Buy ACADIA Pharmaceuticals Stock Online?
In order to purchase ACADIA Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
26
NARI alert for Jan 7
Inari Medical [NARI] is up 30.64% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is up 22.41% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is up 18.99% over the past day.
